Med Care by Naumann, Rebecca B. et al.
Evaluation of a Medicaid Lock-in Program:
Increased Use of Opioid Use Disorder Treatment but No Impact on Opioid Overdose Risk
Rebecca B. Naumann, PhD*, Andrew W. Roberts, PharmD, PhD†, Stephen W. Marshall, 
PhD*, Asheley C. Skinner, PhD‡
*Department of Epidemiology and Injury Prevention Research Center, University of North 
Carolina at Chapel Hill, Chapel Hill, NC
†Department of Preventive Medicine and Public Health, University of Kansas Medical Center, 
Kansas City, KS
‡Duke Clinical Research Institute, Durham, NC
Abstract
Background:  “Lock-in” programs (LIPs) identify beneficiaries demonstrating potential 
overutilization of opioids, and other controlled substances, and restrict their access to these 
medications. LIPs are expanding to address the opioid crisis and could be an effective tool for 
connecting people to opioid use disorder treatment. We examined the immediate and sustained 
effects of a Medicaid LIP on overdose risk and use of medication-assisted treatment (MAT) for 
opioid use disorder.
Methods: We analyzed North Carolina Medicaid claims from July 2009 through June 2013. We 
estimated daily risk differences and ratios of MAT use and overdose during lock-in and following 
release from the program, compared with periods before program enrollment.
Results: The daily probability of MAT use during lock-in and following release was greater, 
when compared with a period just before LIP enrollment [daily risk ratios: 1.50, 95% confidence 
interval (CI): 1.18–1.91; 2.27, 95% CI: 1.07–4.80; respectively]. Beneficiaries’ average overdose 
risk while enrolled in the program and following release was similar to their risk just before 
enrollment (daily risk ratios: 1.01, 95% CI: 0.79–1.28; 1.12, 95% CI: 0.82–1.54; respectively).
Discussion: North Carolina’s Medicaid LIP was associated with increased use of MAT during 
enrollment, and this increase was sustained in the year following release from the program. 
However, we did not observe parallel reductions in overdose risk during lock-in and following 
release. Identifying facilitators of MAT access and use among this population, as well as potential 
barriers to overdose reduction are important next steps to ensuring effective LIP design.
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Between 2000 and 2016, >300,000 people died from an opioid overdose with a death rate in 
2016 > 4 times that of 2000 (3.0 vs. 13.3 per 100,000 population).1 Parallel increases in 
opioid use disorders (OUDs) have been documented.2
Several policies and programs have been implemented in an attempt to reduce OUD and 
overdose.3 In some cases, established programs for controlling health care utilization have 
been reframed to address the current public health emergency. For example, beneficiary 
“lock-in” programs (LIPs) originated in Medicaid in the 1970s as a tool to reduce fraud, 
waste, and abuse of Medicaid resources.4,5 LIPs were implemented to identify beneficiaries 
exhibiting high use of prescription-controlled substances and to control access to these 
medications by requiring them to use, typically, a single prescriber and/or pharmacy to 
obtain these drugs for a specified period of time (eg, 1–2 y). As opioid use, OUD, and 
overdose increased, LIPs received renewed attention and their use proliferated as a means to 
reduce not only fraud and waste, but also OUD and overdose.4,5 Although research indicates 
that LIPs reduce controlled substance prescription claims and plan expenditures for 
beneficiaries enrolled in the LIP,4,6–13 their larger impact as a repurposed tool to improve 
patient and public health outcomes is unknown.
We previously reported on the impacts of North Carolina’s (NC) Medicaid LIP on opioid 
prescriptions dispensed to those enrolled in the program. We found that the program was 
associated with reductions in numbers of Medicaid claims for opioid prescriptions per 
person per month.14,15 However, our findings also suggested that numbers of opioids 
obtained through out-of-pocket payment increased.15,16 Furthermore, average dosages of 
opioids dispensed [in terms of average daily morphine milligram equivalents (MMEs)] to 
beneficiaries were elevated during LIP enrollment.15 The increases in out-of-pocket 
payments and average daily MMEs among LIP enrollees raise concerns about patient 
clinical outcomes and public health effects of LIPs related to OUD and overdose. Therefore, 
the objective of this study was to examine impacts of NC’s Medicaid LIP on overdose risk 
and use of medication-assisted treatment (MAT) for OUD among beneficiaries. We assessed 
both immediate (during program enrollment) and sustained (following program release) 
impacts of the program on these outcomes.
METHODS
NC’s Medicaid LIP
The NC Medicaid LIP was implemented in October 2010.17 Medicaid beneficiaries were 
eligible for the LIP if they had, within 2 consecutive calendar months: (1) >6 opioid claims, 
(2) >6 benzodiazepine claims, or (3) opioid or benzodiazepine claims prescribed by > 3 
different prescribers.17 A prioritization process resulted in about 200 LIP-eligible 
beneficiaries selected for enrollment each month. Once enrolled, beneficiaries were 
restricted to using 1 prescriber and 1 pharmacy location to receive NC Medicaid coverage of 
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opioid and benzodiazepine prescriptions for a 1-year period. Additional details of the 
implementation and administration of NC’s Medicaid LIP, as well as how the NC Medicaid 
population compares with other Medicaid populations, have been previously reported.18
Data, Study Design, and Cohort
Data included NC Medicaid claims from July 2009 through June 2013. We established and 
followed a cohort of independent-living adults, aged 18–64, who became eligible for the LIP 
between June 2010 and June 2013. Because the objective was to examine the association 
between the program and the outcomes of MAT and overdose, we included beneficiaries 
who became eligible for the LIP by meeting the opioid-specific criterion ( > 6 opioid 
prescriptions). Approximately 97% of those enrolled in the LIP met this criterion.18 We 
included those who became eligible for the LIP between June 2010 and June 2013 because 
the first assessment period for program eligibility was June–July 2010 (for the first LIP 
enrollment in October 2010) and we had data through June 2013. We followed beneficiaries 
in our cohort from the first day they received any opioid prescription in our data, throughout 
their period of lock-in, and up to 1 year following program release or until the end of our 
dataset, whichever came first. This study was approved by the University of North Carolina 
at Chapel Hill’s Institutional Review Board.
Classification of LIP Observation Periods
To examine immediate and sustained associations between the LIP and outcomes, we 
divided beneficiaries’ observation time into 4 segments: 2 pre-program enrollment periods 
(“pre-LIP eligibility” and “post-LIP eligibility”), a 12-month program period (lock-in), and a 
period after program release (release). We divided pre-program time into 2 periods to allow 
for comparisons to 2 distinct periods of interest to the LIP: (1) a “pre-LIP eligibility” period 
included time from a beneficiary’s first opioid prescription in our claims data until they met 
the LIP opioid eligibility criterion and (2) a “post-LIP eligibility” period included time from 
meeting LIP eligibility until actual program enrollment, if enrolled. As noted above, due to 
the LIP prioritization process, some beneficiaries met LIP criteria but were never enrolled. 
The “lock-in” period included up to 12 months of program time, and the “release” period 
included up to 12 months following program release.
Outcomes
We estimated the daily probability of MAT use for an OUD and the risk of overdose across 
LIP-related periods. Receipt of MAT was defined as having an active prescription for a 
buprenorphine product indicated for use of OUD treatment on a given day or any mention of 
CPT code H0020 for methadone treatment on a given day.19,20 Overdose, was defined using 
the following ICD-9-CM codes 960–979 or E-codes: E850–E858, E950.0–E950.5, E962.0, 
E980.0–E980.5.21,22 See Supplementary Material, Supplemental Digital Content 1, (http://
links.lww.com/MLR/B676) for additional details on outcome assessment and sensitivity 
analyses.
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Covariates and Propensity Scores
To isolate the effects of the LIP on outcomes and control for potential confounding, we 
identified a comparison group of NC Medicaid beneficiaries that met LIP eligibility criteria 
but were not enrolled in the program due to program capacity limitations. We constructed 
propensity scores estimating the probability of LIP enrollment conditional on baseline 
covariates using logistic regression.23 Covariates included demographic characteristics, 
health care utilization, and medical diagnoses.15,18 Specific information on claims-related 
codes used to define characteristics and a figure displaying the propensity score distribution 
for LIP-enrolled and not enrolled groups are available in the Supplement, Supplemental 
Digital Content 1 (http://links.lww.com/MLR/B676).
Statistical Analyses
We compared the prevalence of demographic characteristics, health care utilization, and 
medical diagnoses among LIP-enrolled and not enrolled groups. For categorical variables, 
we calculated percentages, and for continuous variables, means and SDs.
We examined crude counts and rates of MAT and overdose by LIP-related periods. We used 
generalized estimating equations to estimate measures of association (daily risk differences 
and ratios) between lock-in and release periods, compared with the pre-LIP enrollment 
reference periods, and the average risk of MAT and overdose. We included stabilized inverse 
probability of LIP enrollment weights (calculated using the propensity scores described 
above) in models.23 See Supplement for additional details, Supplemental Digital Content 1 
(http://links.lww.com/MLR/B676). Models also included linear secular trend variables to 
help control for changes in awareness and opioid prescribing culture and use during this 
time.
RESULTS
Between June 2010 and June 2013, 17,823 NC Medicaid beneficiaries were eligible for 
enrollment in the LIP, and 31% (n = 5479) were enrolled. Crude rates of MAT and overdose 
generally increased across pre-LIP, during, and release periods (Table 1).
Table 2 compares the demographic characteristics, health care utilization, and medical 
diagnoses of those enrolled versus not enrolled in the LIP. See Supplement, Supplemental 
Digital Content 1 (http://links.lww.com/MLR/B676) for comparisons after inverse 
probability of LIP enrollment weighting.
Including inverse probability of enrollment weights and adjusting for temporal trend, the 
daily probability of MAT use during lock-in and post-release was greater, compared with 
time before meeting LIP criteria (Table 3; Fig. S2 in Supplement, Supplemental Digital 
Content 1, http://links.lww.com/MLR/B676). Moreover, the daily probability of MAT use 
during lock-in and following release remained greater, when compared with a period after 
program criteria had been met, but before program enrollment (post-LIP eligibility period). 
Compared with the post-LIP eligibility period, 9 more beneficiaries per 1000 accessed MAT 
per day during lock-in [95% confidence interval (CI): 3.80–14.18] and 25 more following 
release (95% CI: −5.14 to 54.29).
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Beneficiaries’ average overdose risk was also elevated while enrolled in the program and 
following release when compared with their risk before meeting program criteria (Table 4; 
Fig. S2 in Supplement, Supplemental Digital Content 1, http://links.lww.com/MLR/B676). 
However, overdose risks during the program and following release were similar to that 
observed after meeting program eligibility criteria but before enrollment [daily risk ratios: 
1.01, 95% CI: 0.79–1.28; 1.12, 95% CI: 0.82–1.54, respectively].
DISCUSSION
Among a population characterized by high opioid use, we found that LIP enrollment was 
associated with increased use of MAT for OUD, when compared with a period just before 
program enrollment (post-LIP eligibility). However, there were no corresponding reductions 
in average overdose risk. Both of these findings were sustained in the year following release 
from the program.
Although previous research has documented high opioid overdose death rates among those 
enrolled in a LIP, this is the first study to specifically examine daily overdose risk across 
program-related periods.24 Ideally, LIPs would result in improved care coordination, 
connection to appropriate OUD treatment as needed, and reduction in overdose. Although 
findings suggested an average increase in MAT use for OUD, these increases did not couple 
with overdose decreases. However, given previous analyses indicating an increase in average 
daily MMEs across LIP enrollment and release periods, when compared with pre-program 
time, a reduction in overdose risk would have been incongruous.15 In addition, the extent to 
which LIP restrictions may induce enrollees to obtain substances outside of the health care 
system is unknown and could also affect overdose risk across these periods. Further research 
looking at specific opioids involved in overdoses among LIP enrollees, particularly during 
the more recent increase in synthetic opioid-related (eg, fentanyl) deaths, is also warranted.
Our findings suggest that LIPs may provide a useful framework for connecting high-risk 
patients with diagnosed or undiagnosed OUD with MAT. Although there are examples of 
LIPs applying an intensive case management approach to ensure the provision of MAT and 
other necessary ancillary medical services, many still do not.25,26 Specifically, use of 
motivational interviewing, peer-to-peer support, and assessment and connection to resources 
for treatment of comorbid conditions (eg, mental health disorders) and other critical needs 
(eg, transportation resources to MAT) are examples of promising starting points. Evaluations 
of programs that include such a tailored approach, including estimation of their effects on 
key public health outcomes and on short-term and long-term costs and benefits, would 
provide critical information to LIP administrators.
This study was subject to at least 4 limitations. First, we did not have information on 
overdoses that did not generate a Medicaid claim. Second, we did not have information on 
out-of-pocket payments made at methadone clinics or for out-of-pocket MAT-related 
buprenorphine prescriptions. To assess the impact of this, we examined data on out-of-
pocket payments for buprenorphine prescriptions, obtained through linkage to the state’s 
prescription drug monitoring program, for those enrolled in the LIP (we only had access to 
linked data on the LIP-enrolled group). We found that out-of-pocket payments constituted a 
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small proportion of all buprenorphine dispensed, with little change across LIP-related 
periods. Third, the presence of diagnoses and health care utilization measures in the year 
before meeting LIP eligibility may be underestimated for some, given variable amounts of 
data available on those before LIP eligibility. However, research suggests that inclusion of 
any available data in a lookback period to assess presence of covariates results in less mis-
classification than restricting to a common lookback period.27 Fourth, administrative 
censoring resulted in loss of follow-up in the 1-year post-release period. It is possible that 
losses to follow-up were related to our outcome measures and could have introduced some 
bias when estimating measures of association involving the post-release period.
NC’s Medicaid LIP was associated with increased use of MAT during enrollment, and this 
increase was sustained in the year following release from the program. However, we did not 
observe parallel reductions in overdose risk during lock-in and following release, when 
compared with just before LIP enrollment. Identifying facilitators of MAT access and use 
among this population, as well as potential barriers to overdose reduction are important next 
steps to ensuring effective LIP design.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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TABLE 2.
Characteristics of North Carolina Medicaid Beneficiaries Eligible for the LIP by Program Enrollment Status, 
July 2009 to June 2013 (N = 17,823)
Percentage or Mean (SD)
Enrolled (N=5479) Not Enrolled (N=12,344)
Demographics*
 Age group (y)
  18-24 11.0  9.3
  25-34 34.9 26.7
  35-44 28.7 25.6
  45-54 18.6 24.6
  55-64  6.8 13.8
 Women 69.3 64.2
 Race
  White 76.5 74.9
  Black 17.9 19.9
  Other (eg, Asian, Pacific Islander)  3.4  2.6
  Unreported  2.2  2.6
 Medicaid aid category code
  Aid to families with dependent children 61.3 52.2
  Aid to disabled 35.2 44.4
  Other (eg, aid to blind)  3.5  3.5
Health care utilization†
 Medical care utilization
  No. emergency department visits 7.4 (9.7) 3.9 (5.1)
  No. inpatient admissions 3.6 (9.4) 3.5 (9.2)
 Pharmacy utilization
  Unique pharmacies visited 3.9 (2.5) 2.8 (1.8)
  No. opioid prescriptions when LIP criteria met 8.0 (1.3) 7.6 (1.0)
 Medication-assisted treatment
  Any methadone treatment  1.7  0.8
  Any buprenorphine prescription dispensed‡ 3.1 0.9
Medical diagnoses†
 Pain-related diagnoses
  Any joint pain or arthritis 81.5 77.0
  Back pain 74.7 61.2
  Neck pain 32.8 26.2
  Headache/migraine 18.4 13.5
  Fibromyalgia, chronic pain, or fatigue 36.7 29.5
  Rheumatoid arthritis or osteoarthritis 17.2 15.9
 Mental health diagnoses
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Percentage or Mean (SD)
Enrolled (N=5479) Not Enrolled (N=12,344)
  Depression 49.3 40.5
  Bipolar disorder 15.4 10.4
  Personality disorder  2.8  1.3
  Anxiety disorder 31.4 21.3
  Posttraumatic stress disorder  5.2  3.1
 Substance use-related diagnoses
  Any overdose  5.0  3.0
  Alcohol-related disorder  5.9  5.7
  Other substance-related disorder 20.6 12.0
 Other comorbid conditions
  Mean Charlson comorbidity index 0.7 (1.4) 1.5 (2.7)
  Cancer  0.6 12.9
*Assessed at time of meeting LIP eligibility.
†Assessed using a 1-year look-back period from point of meeting LIP eligibility.
‡
Buprenorphine prescription indicated for treatment of substance use disorder.
LIP indicates “lock-in” program.
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TABLE 4.
Average Adjusted* Daily Risks and Risk Ratios† of Overdose Comparing LIP-related Periods, July 2009 to 
June 2013 (N = 17,823)
Reference Period: Pre-LIP 
Eligibility Period
Reference Period: Post-LIP 
Eligibility Period
Program-related Period
Model-estimated Daily Risk Per 
1000 Pop (95% CI)‡ Risk Ratio (95% CI) Risk Ratio (95% CI)
Pre-LIP eligibility 0.16 (0.14–0.19) Ref
Post-LIP eligibility 0.22 (0.18–0.28) 2.04 (0.99–4.21) Ref
Lock-in 0.22 (0.18–0.26 2.06 (1.10–3.86) 1.01 (0.79–1.28)
Release 0.22 (0.16–0.29) 2.29 (0.95–5.46) 1.12 (0.82–1.54)
*
Inverse probability of enrollment weighted and adjusted for secular trend.
†
Linear-binomial generalized estimating equation models for overdose risk had convergence issues; therefore, risk differences are not presented.
‡
Estimated from adjusted log-binomial generalized estimating equation model, using median value of secular trend for each period.
CI indicates confidence interval; LIP, “lock-in” program; Pop, population; Ref, reference.
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